SCHEMBL30184645

SCHEMBL30184645

C#CCNc1ccc(P(C)(C)=O)cc1C(F)F

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 2/20 0.30
▸ MAOB P27338 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25033233 1.00 MAOA (0.30) MAOAMAOB
SCHEMBL25030921 0.84 MAPT (0.31) —
SCHEMBL25033451 0.80 SMN1; SMN2 (0.34) —
SCHEMBL25033427 0.78 MAOA (0.35) MAOAMAOB
SCHEMBL30184453 0.77 ALDH1A1 (0.33) —
SCHEMBL25033103 0.77 ALDH1A1 (0.33) —
SCHEMBL25033063 0.75 INSR (0.41) MAOA
SCHEMBL30871276 0.75 INSR (0.41) MAOA
SCHEMBL25033172 0.75 RECQL (0.34) —
SCHEMBL30184488 0.75 INSR (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676602-A1 COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF Merck Sharp & Dohme LLC (US) 2026-01-14 — — EP disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
WO-2024187153-A1 COMPOUNDS TARGETING MUTATIONS IN P53 AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-09-12 — — WO disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 — — EP disclosed
CN-117813295-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2024-04-02 — — CN disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 MAOA 4207/4885MAOB 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback